Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$3.3MFederal grants as PI5 awards
2Patents grantedLatest Jun 21, 2022
71Papers2,317 citations
Federal awards and patents by year
AwardsPatents
5 awards · $3.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 26, 2017 | NIH | SBIR Phase II An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $1000K | Pulmokine, Inc. |
| Aug 4, 2016 | NIH | SBIR Phase II An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $999K | Pulmokine, Inc. |
| Apr 7, 2016 | NIH | SBIR Phase I A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma | $337K | Pulmokine, Inc. |
| Jul 31, 2015 | NIH | SBIR Phase II An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $5K | Pulmokine, Inc. |
| Jul 20, 2015 | NIH | SBIR Phase II An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $1000K | Pulmokine, Inc. |
3 patents as inventor
- US 10231966Pulmokine, Inc.Mar 19, 2019
- US 11364238Pulmokine, Inc.Jun 21, 2022
- US Pulmokine, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#557
Awards as PI#470
Patents#185
Companies
- Pulmokine, Inc.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.